BioSpace News Archive

Cagent Vascular Inc., a developer of next generation angioplasty balloons using serration technology, announced the expansion of its product offering to include larger balloons to treat superficial femoral and popliteal arteries in the Above-the-Knee (ATK) segment.

BDO executives to lead discussion panels on business and manufacturing strategies, technology for cell and gene therapy.

Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor, TT-816.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference.

Soligenix, Inc. announced a publication describing the binding of its Innate Defense Regulator, dusquetide, to the p62 protein.

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced, after careful consideration and a review of the company’s future needs, that Perry Genova, Senior Vice President of Research and Product Development, will depart the company effective immediately.

Data presented at 2022 Epilepsy Foundation Pipeline Conference provide additional in vivo proof of concept for CODA’s engineered receptors and activator drugs in controlling seizures.

Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that upon submitting an application to the U.S. Food and Drug Administration its development programme of MTX110 for the treatment of recurrent glioblastoma (“rGBM”) has been granted Fast Track designation by the agency.

CytomX Therapeutics, Inc. announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET.

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences: